Emerging vaccine strategies against the incessant pneumococcal disease.

Authors:
Duke JA; Avci FY.

Journal:
NPJ Vaccines

Publication Year: 2023

DOI:
10.1038/s41541-023-00715-w

PMCID:
PMC10435554

PMID:
37591986

View on PubMed View on PMC View Publisher
Journal Information

Full Title: NPJ Vaccines

Abbreviation: NPJ Vaccines

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Absolute quantitation of binding antibodies from clinical samples.
Tang C; Verwilligen A; Sadoff J and 15 more (2024) - Transparency Score: 3/6
Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine.
MacMillen Z; Hatzakis K; Simpson A and 9 more (2024) - Transparency Score: 3/6
An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron …
Uraki R; Imai M; Ito M and 7 more (2024) - Transparency Score: 3/6
Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vacc…
Chugh S; Bahal RK; Dhiman R and 1 more (2024) - Transparency Score: 3/6
Antigen self-anchoring onto bacteriophage T5 capsid-like particles for vaccine design.
Vernhes E; Larbi Chérif L; Ducrot N and 12 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests J.A.D. is employed by Sanofi, which develops pneumococcal vaccines."

Evidence found in paper:

"This work was supported by National Institutes of Health grants R01AI123383, R01AI152766, and R41AI157287."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025